Convalescent plasma for COVID-19 patients achieved 80% favorable results

Share

The PC-COVID-19 Group revealed that, after completing the pilot phase for this treatment -the first and only one so far authorized by the Colombia National Food and Drug Surveillance Institute (INVIMA)- the randomized controlled trial in which 90 patients will be studied in Colombia has started.

OTHER RELEVANT INFORMATION

CONTACT US

SHAREHOLDER CHAT

Do you have questions? Do you want to make the most of your investment?

Real-time chat. One of our advisors will guide you to clarify doubts about your investment